Thermo Fisher has brought an 85,000-square-foot purification product plant online. This is part of a multi-year $650 million CAPEX spend across its bioprocessing business.

The facility in Chelmsford, Massachusetts is set to supply biomanufacturing customers with downstream technologies, specifically for the purification of biologics and vaccines.

The facility is located at the Chelmsford site – acquired for $11.68 million by Thermo Fisher in 2020 – is part of the firm’s global bioprocessing supply network, which has been subjected to ongoing investments over the past few years, including a $650 million multi-year CAPEX plan announced in 2021.